Literature DB >> 16314558

Interfering with interferons: Hepatitis C virus counters innate immunity.

Eric C Freundt1, Michael J Lenardo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16314558      PMCID： PMC1308935          DOI： 10.1073/pnas.0509221102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  22 in total

Review 1.  Viruses and interferons.

Authors:  G C Sen
Journal:  Annu Rev Microbiol       Date:  2001       Impact factor: 15.500

Review 2.  Transcriptional activation of alpha/beta interferon genes: interference by nonsegmented negative-strand RNA viruses.

Authors:  Karl-Klaus Conzelmann
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

3.  DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection.

Authors:  C B Bigger; K M Brasky; R E Lanford
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF.

Authors:  Kui Li; Eileen Foy; Josephine C Ferreon; Mitsuyasu Nakamura; Allan C M Ferreon; Masanori Ikeda; Stuart C Ray; Michael Gale; Stanley M Lemon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

Review 5.  How cells respond to interferons.

Authors:  G R Stark; I M Kerr; B R Williams; R H Silverman; R D Schreiber
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

Review 6.  Course and outcome of hepatitis C.

Authors:  Jay H Hoofnagle
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

7.  Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling.

Authors:  Masahiro Yamamoto; Shintaro Sato; Kiyotoshi Mori; Katsuaki Hoshino; Osamu Takeuchi; Kiyoshi Takeda; Shizuo Akira
Journal:  J Immunol       Date:  2002-12-15       Impact factor: 5.422

8.  Robust hepatitis C virus infection in vitro.

Authors:  Jin Zhong; Pablo Gastaminza; Guofeng Cheng; Sharookh Kapadia; Takanobu Kato; Dennis R Burton; Stefan F Wieland; Susan L Uprichard; Takaji Wakita; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-06       Impact factor: 11.205

9.  Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3.

Authors:  L Alexopoulou; A C Holt; R Medzhitov; R A Flavell
Journal:  Nature       Date:  2001-10-18       Impact factor: 49.962

10.  An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.

Authors:  Daniel Lamarre; Paul C Anderson; Murray Bailey; Pierre Beaulieu; Gordon Bolger; Pierre Bonneau; Michael Bös; Dale R Cameron; Mireille Cartier; Michael G Cordingley; Anne-Marie Faucher; Nathalie Goudreau; Stephen H Kawai; George Kukolj; Lisette Lagacé; Steven R LaPlante; Hans Narjes; Marc-André Poupart; Jean Rancourt; Roel E Sentjens; Roger St George; Bruno Simoneau; Gerhard Steinmann; Diane Thibeault; Youla S Tsantrizos; Steven M Weldon; Chan-Loi Yong; Montse Llinàs-Brunet
Journal:  Nature       Date:  2003-10-26       Impact factor: 49.962
View more
  7 in total

1.  Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users.

Authors:  J K Flynn; G J Dore; M Hellard; B Yeung; W D Rawlinson; P A White; J M Kaldor; A R Lloyd; R A Ffrench
Journal:  J Viral Hepat       Date:  2010-07-05       Impact factor: 3.728

2.  Proapoptotic IL-18 in patients with chronic hepatitis C treated with pegylated interferon-alpha.

Authors:  He YingLi; Lin Shumei; Yang Qian; Chen Tianyan; Zhao Yingren; Chen Wei
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

3.  Molecular determinants for subcellular localization of the severe acute respiratory syndrome coronavirus open reading frame 3b protein.

Authors:  Eric C Freundt; Li Yu; Elizabeth Park; Michael J Lenardo; Xiao-Ning Xu
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

4.  Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.

Authors:  Huiling Yang; Margaret Robinson; Amoreena C Corsa; Betty Peng; Guofeng Cheng; Yang Tian; Yujin Wang; Rowchanak Pakdaman; Marian Shen; Xiaoping Qi; Hongmei Mo; Chin Tay; Steve Krawczyk; X Christopher Sheng; Choung U Kim; Chris Yang; William E Delaney
Journal:  Antimicrob Agents Chemother       Date:  2013-08-12       Impact factor: 5.191

5.  GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo.

Authors:  Pei-Bin Zhai; Jie Qing; Ben Li; Lin-Qi Zhang; Lan Ma; Li Chen
Journal:  Acta Pharmacol Sin       Date:  2018-06-21       Impact factor: 6.150

6.  Involvement of Differential Relationship between HCV Replication and Hepatic PRR Signaling Gene Expression in Responsiveness to IFN-Based Therapy.

Authors:  Nobukazu Yuki; Shinji Matsumoto; Michio Kato; Toshikazu Yamaguchi
Journal:  Hepat Res Treat       Date:  2013-12-29

7.  HCV NS3 Blocking Effect on IFN Induced ISGs Like Viperin and IL28 With and Without NS4A.

Authors:  Zahra Khanlari; Farzaneh Sabahi; Seyed Younes Hosseini; Mostafa Ghaderi
Journal:  Hepat Mon       Date:  2014-06-08       Impact factor: 0.660
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.